Day One Biopharmaceuticals (DAWN) Competitors $12.71 +0.07 (+0.55%) (As of 09:39 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends DAWN vs. CRNX, KRYS, ACLX, ADMA, BHVN, RARE, APLS, IMVT, RNA, and SRRKShould you be buying Day One Biopharmaceuticals stock or one of its competitors? The main competitors of Day One Biopharmaceuticals include Crinetics Pharmaceuticals (CRNX), Krystal Biotech (KRYS), Arcellx (ACLX), ADMA Biologics (ADMA), Biohaven (BHVN), Ultragenyx Pharmaceutical (RARE), Apellis Pharmaceuticals (APLS), Immunovant (IMVT), Avidity Biosciences (RNA), and Scholar Rock (SRRK). These companies are all part of the "pharmaceutical products" industry. Day One Biopharmaceuticals vs. Crinetics Pharmaceuticals Krystal Biotech Arcellx ADMA Biologics Biohaven Ultragenyx Pharmaceutical Apellis Pharmaceuticals Immunovant Avidity Biosciences Scholar Rock Crinetics Pharmaceuticals (NASDAQ:CRNX) and Day One Biopharmaceuticals (NASDAQ:DAWN) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation, community ranking and media sentiment. Do analysts prefer CRNX or DAWN? Crinetics Pharmaceuticals currently has a consensus target price of $70.82, suggesting a potential upside of 28.92%. Day One Biopharmaceuticals has a consensus target price of $35.71, suggesting a potential upside of 180.99%. Given Day One Biopharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Day One Biopharmaceuticals is more favorable than Crinetics Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Crinetics Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.91Day One Biopharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has more risk & volatility, CRNX or DAWN? Crinetics Pharmaceuticals has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500. Comparatively, Day One Biopharmaceuticals has a beta of -1.51, meaning that its stock price is 251% less volatile than the S&P 500. Which has better earnings & valuation, CRNX or DAWN? Day One Biopharmaceuticals has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Day One Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCrinetics Pharmaceuticals$1.04M4,902.89-$214.53M-$3.73-14.73Day One Biopharmaceuticals$101.95M12.57-$188.92M-$1.03-12.34 Does the MarketBeat Community prefer CRNX or DAWN? Crinetics Pharmaceuticals received 110 more outperform votes than Day One Biopharmaceuticals when rated by MarketBeat users. Likewise, 69.20% of users gave Crinetics Pharmaceuticals an outperform vote while only 66.18% of users gave Day One Biopharmaceuticals an outperform vote. CompanyUnderperformOutperformCrinetics PharmaceuticalsOutperform Votes15569.20% Underperform Votes6930.80% Day One BiopharmaceuticalsOutperform Votes4566.18% Underperform Votes2333.82% Is CRNX or DAWN more profitable? Day One Biopharmaceuticals' return on equity of -22.40% beat Crinetics Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Crinetics PharmaceuticalsN/A -36.12% -31.89% Day One Biopharmaceuticals N/A -22.40%-19.79% Do insiders and institutionals hold more shares of CRNX or DAWN? 98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. Comparatively, 87.9% of Day One Biopharmaceuticals shares are held by institutional investors. 6.0% of Crinetics Pharmaceuticals shares are held by company insiders. Comparatively, 8.4% of Day One Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media refer more to CRNX or DAWN? In the previous week, Crinetics Pharmaceuticals had 6 more articles in the media than Day One Biopharmaceuticals. MarketBeat recorded 12 mentions for Crinetics Pharmaceuticals and 6 mentions for Day One Biopharmaceuticals. Crinetics Pharmaceuticals' average media sentiment score of 1.12 beat Day One Biopharmaceuticals' score of 0.49 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crinetics Pharmaceuticals 6 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Day One Biopharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryDay One Biopharmaceuticals beats Crinetics Pharmaceuticals on 10 of the 18 factors compared between the two stocks. Ad Porter & CompanyHow to piss off your liberal friends… and profit from itElon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.To get the full details on the fake “energy crisis” of America, watch this now Get Day One Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for DAWN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DAWN vs. The Competition Export to ExcelMetricDay One BiopharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.28B$6.85B$5.15B$9.28BDividend YieldN/A3.06%4.81%4.06%P/E Ratio-12.3410.79135.4217.51Price / Sales12.57286.571,184.62142.21Price / CashN/A56.6540.4237.95Price / Book3.195.404.894.94Net Income-$188.92M$152.04M$118.71M$225.59M7 Day Performance-3.42%-4.19%15.74%-1.07%1 Month Performance-2.31%2.70%15.70%7.23%1 Year Performance-10.30%17.16%34.85%22.97% Day One Biopharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DAWNDay One Biopharmaceuticals1.9456 of 5 stars$12.71+0.6%$35.71+181.0%-11.4%$1.28B$101.95M-12.3460CRNXCrinetics Pharmaceuticals4.2151 of 5 stars$54.49+1.5%$70.82+30.0%+60.7%$5.05B$1.04M-14.54210Analyst ForecastShort Interest ↓Positive NewsKRYSKrystal Biotech4.3121 of 5 stars$166.71+1.9%$206.67+24.0%+46.0%$4.79B$50.70M92.45229Analyst ForecastACLXArcellx3.2007 of 5 stars$83.55-0.3%$105.93+26.8%+60.5%$4.52B$155.82M-118.03130ADMAADMA Biologics3.8605 of 5 stars$18.92+1.8%$21.25+12.3%+343.6%$4.47B$382.81M67.57530Short Interest ↓BHVNBiohaven3.8327 of 5 stars$41.93+9.0%$63.00+50.3%+0.3%$4.24B$462.51M-4.48239Analyst ForecastNews CoverageRAREUltragenyx Pharmaceutical4.5688 of 5 stars$45.52-0.6%$87.46+92.1%-2.2%$4.20B$434.25M-7.081,276APLSApellis Pharmaceuticals4.721 of 5 stars$33.39+0.6%$49.94+49.6%-34.5%$4.15B$396.59M-16.35702Analyst DowngradeShort Interest ↓Positive NewsIMVTImmunovant1.4499 of 5 stars$27.56+4.9%$47.89+73.8%-34.7%$4.05BN/A-11.84120RNAAvidity Biosciences2.5121 of 5 stars$33.46+3.0%$63.60+90.1%+278.5%$3.99B$10.12M-11.28190Gap DownSRRKScholar Rock3.9591 of 5 stars$42.48+1.2%$40.43-4.8%+130.0%$3.98B$33.19M-18.35140Positive News Related Companies and Tools Related Companies Crinetics Pharmaceuticals Competitors Krystal Biotech Competitors Arcellx Competitors ADMA Biologics Competitors Biohaven Competitors Ultragenyx Pharmaceutical Competitors Apellis Pharmaceuticals Competitors Immunovant Competitors Avidity Biosciences Competitors Scholar Rock Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:DAWN) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored2025’s #1 Trump TradeAll the Energy You Need to Power Your Entire Life... Could Fit Inside This Single Soda Can. Three Companies...The Oxford Club | Sponsored50-year Wall Street legend: “Sell this tech stock NOW”Something very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | SponsoredThis drone stock is setting up to transform medical supply deliveryDrone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.The Tomorrow Investor | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Day One Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Day One Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DAWN Stock Alerts